SOURCE: Procyon Corporation

May 06, 2008 13:00 ET

Procyon Corporation Announces Amerx Healthcare Subsidiary Has Obtained #1 Ranking in Podiatry Management's 25th Annual Survey for Amerigel Wound & Skin Care Products

CLEARWATER, FL--(Marketwire - May 6, 2008) - Procyon Corporation (OTCBB: PCYN), a Clearwater, Florida-based company whose subsidiaries include Amerx Health Care Corporation -- -- today announced that the recently published "Podiatry Management 25th Annual Survey" of podiatrists places Amerigel® at the top of two lists regarding physician recommended treatment products. D.P.M.'s from around the nation were asked to respond to survey questions to determine industry trends.

According to the Annual Survey, Amerigel® was ranked as the #1 topical dressing of choice following matrixectomy for the 5th consecutive year. Amerigel® Wound Dressing represented a definitive lead over other topical dressings recommended for post-matrixectomy treatment with 45% of the respondents reporting it as their first choice for treatment, a 17% increase over the previous year's percentage. Amerigel® was named the treatment of choice by more podiatrists than all the other name brands that were included in the survey combined.

Amerigel® Wound Dressing was also ranked as the #1 product recommended for non-graft treatment of wounds and ulcers for the second straight year. Twenty-three percent of the respondents reported that they recommended Amerigel® for non-graft wound/ulcer treatments, an 8% increase over the previous year's response.

Amerigel® products carry the APMA Seal of Approval. Amerigel® products are made with a proprietary product rich with natural tannins, known as Oakin®. Oakin®, exclusive to the Amerigel® product line, delivers these known benefits to patients in need of solving skin and wound problems.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: When used in this release, the words "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," and similar expressions, variations or the negative of these words, and any statement regarding possible or assumed future results of operations of our business, the markets for our products, anticipated expenditures, regulatory developments or competition, or other statements regarding matters that are not historical facts, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements are subject to various risks and uncertainties, including, but not limited to, the following: business conditions in the skin and wound care market and the general economy, competitive factors, changes in product mix, production delays, manufacturing capabilities, and other risks or uncertainties detailed in other of the Company's Securities and Exchange Commission filings. Additional information on these and other factors that could affect our financial results is included in our Form 10-KSB for the year ended June 30, 2006. There may be other factor not mentioned above, in the discussion below or included in our Securities and Exchange Commission filings that may cause actual results to differ materially from any forward-looking statements. The reader should not place undue reliance on any forward-looking statements. Neither the Company nor any of its corporate officers or key employees assumes any obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Contact Information

  • Regina Anderson
    Procyon Corporation